Welcome to the Multiple Sclerosis Outcome Assessments Consortium (MSOAC) Placebo Database

Data contained in this database:

Placebo arms from clinical trial datasets, which were contributed by industry members of MSOAC, are aggregated in the MSOAC Placebo Database. The MSOAC Placebo Database presently includes 2465 individual patient records from 9 clinical trials. This version 1.0 includes records from relapsing-remitting, secondary progressive, and primary progressive forms of MS.

The C-Path Data Collaboration Center (DCC) database contains, but is not limited to, data on demographics, medical history, performance outcome measures [e.g. Timed 25 Foot Walk (T25FW), 9-Hole Peg Test (9HPT), Paced Auditory Serial Addition Test (PASAT), Low Contrast Visual Acuity (LCVA)], clinician reported outcome measures [e.g. Expanded Disability Status Scale (EDSS)], patient reported outcome measures [e.g. 36-Item Short Form Health Survey (SF-36)], relapse information, and MS type (e.g. relapsing-remitting).

How the data are standardized:

The data are re-mapped to the current Clinical Data Interchange Standard Consortium (CDISC) foundational standard (SDTMIG v3.2).  Knowledge of SDTM is necessary for effective interpretation of these data.

All data are fully anonymized and de-identified. Also, the individual clinical trials are not identified in this pooled placebo database.

What is NOT in the C-Path DCC database:

1. Treatment data
2. Standard-of-care or active comparator data
3. Imaging data

Accessibility

The MSOAC Placebo data is available to qualified researchers who submit, and are approved for, a request for access.

Frequently Asked Questions